title: Treatment of gastric precancerous lesions with Weiansan.
abstract: OBJECTIVE
  To observe the curative effect of Weiansan (WAS) on gastric precancerous lesions (GPL) and H pylori elimination.
  
  
  METHODS
  Seventy-six patients with GPL were randomly divided into two groups: WAS group (n = 42) and Weifuchun (WFC) group (n = 34). The patients in the WAS group were administered 5 g WAS 3 times a day, and the patients in the WFC group took WFC (4 tablets) 3 times a day. To monitor inflammation of gastric mucosa, degree of glandular atrophy (GA), intestinal metaplasia (IM) and dysplasia, and H pylori infection, all patients underwent gastroscopy and biopsy with pathological examination before and after treatment. Fifty male Sprague-Dawley (SD) rats were used in animal experiments. Of these, 10 served as the control group (n = 10), 40 were given ranitidine combined with N-methyl-N(1)-nitro-N-nitrosoguanidine (MNNG) for 12 wk and divided into 4 groups randomly: model group (n = 10), high-dose WAS group (n = 10), low-dose WAS group (n = 10) and WFC group (n = 10). Twelve weeks later, all rats were killed and a 2 cm multiply 1 cm tissue was taken from the lesser curvature of the gastric antrum. H pylori infection was determined by the fast urease method.
  
  
  RESULTS
  The curative effect in WAS groups was similar to that in WFC groups. There was no statistical difference in degree of GA, IM and dysplasia between WAS and WFC groups. The rate of H pylori infection in the model group (positive/negative: 9/1) was significantly higher than that in the control group (positive/negative: 1/9) (P < 0.01). H pylori elimination in the high-dose WAS group (positive/negative: 4/6) and low-dose WAS group (positive/negative: 6/4) was similar to that in the WFC group (positive/negative: 4/6) (P > 0.05).
  
  
  CONCLUSIONS
  WAS improves clinical symptoms by suppressing GA, IM and dysplasia and eliminating H pylori.
authors.affiliation: Department of Digestive System Diseases, 2nd Affiliated Hospital of Tianjin Traditional Chinese Medicine College, Zhenli Street No. 816, Hebei District, Tianjin 300150, China. ctjenny@eyou.com
authors.forename: Hui-Zhen
authors.initials: HZ
authors.lastname: Li
authors.forename: Hong
authors.initials: H
authors.lastname: Wang
authors.forename: Guan-Qun
authors.initials: GQ
authors.lastname: Wang
authors.forename: Jie
authors.initials: J
authors.lastname: Liu
authors.forename: Shuang-Mei
authors.initials: SM
authors.lastname: Zhao
authors.forename: Jie
authors.initials: J
authors.lastname: Chen
authors.forename: Qing-Wu
authors.initials: QW
authors.lastname: Song
authors.forename: Wang
authors.initials: W
authors.lastname: Gao
authors.forename: Xiang-Zheng
authors.initials: XZ
authors.lastname: Qi
authors.forename: Qiang
authors.initials: Q
authors.lastname: Gao
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000378:metabolism; D006801:Humans; D008297:Male; D008516:Medicine, Chinese Traditional; D008769:Methylnitronitrosoguanidine / Q000494:pharmacology; D008875:Middle Aged; D011230:Precancerous Conditions / Q000188:drug therapy*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013272:Stomach Diseases / Q000188:drug therapy*; D013274:Stomach Neoplasms / Q000517:prevention & control*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D008769:Methylnitronitrosoguanidine